Orphalan
Paris, FR · 146 employees on LinkedIn · 2 known investors
Find your way into Orphalan
Orphalan develops and commercializes innovative therapies for patients with rare diseases, with a focus on unmet medical needs where current treatments are limited or absent. The company has successfully brought trientine tetrahydrochloride (Cuprior®/Cuvrior®) to market for Wilson disease treatment across 30+ countries.
Founders & leadership
MB
Massimo BorieroinFounder
DP
Dmitry ParamonovinFounder
JF
John Fatuhi
SB
Sandra BensoussaninFounder
AB
Angelita BriffainFounder
OC
Omar Camille Kamlin
HB
Hugues BienaymeinFounder
NZ
Nabeel ZubairinFounder
MP
Margot Pisani
SK
Sujatha Karoor
IS
Ivo SulovskyinFounder
Board
NA
Naseem Amin
Investors · 2
In the news
Frequently asked questions
- What does Orphalan do?
- Orphalan develops and commercializes innovative therapies for patients with rare diseases, with a focus on unmet medical needs where current treatments are limited or absent. The company has successfully brought trientine tetrahydrochloride (Cuprior®/Cuvrior®) to market for Wilson disease treatment across 30+ countries.
- Who are Orphalan's investors?
- Orphalan's investors include Advent Life Sciences, Bpifrance.
- Where is Orphalan headquartered?
- Orphalan is headquartered in Paris, FR.